1
/
3
Positive results of selinexor in relapsed and refractory myeloma patients presented at ASH 2019
ASH 2019 Pre-clinical updates
ASH 2019 - Real World Evidence
Bispecific antibodies at ASH 2019
ASH 2019 updates on Minimal Residual Disease (MRD)
ASH 2019 updates on Minimal Residual Disease (MRD) - Italian
ASH 2019 CAR-T cell therapy in myeloma
ASH 2019 Myeloma updates
Results of the clinical trial CANDOR at ASH 2019
Results of the clinical trial CANDOR at ASH 2019 (German)
ASH 2019 - AL amyloidosis highlights
Myeloma and AL amyloidosis updates (Hebrew)
Dreamm-3 and belantamab mafodotin, a new myeloma drug
Dreamm-3 and belantamab mafodotin, a new myeloma drug (German)
ASH 2019 preview
1
/
3